SELLAS Life Sciences Group (NASDAQ:SLS) Issues Quarterly Earnings Results

SELLAS Life Sciences Group (NASDAQ:SLS) posted its quarterly earnings results on Thursday. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03, Zacks reports. During the same quarter last year, the firm posted ($1.34) EPS.

SELLAS Life Sciences Group Price Performance

Shares of SELLAS Life Sciences Group stock traded down $0.04 during trading hours on Friday, hitting $1.18. The company had a trading volume of 200,819 shares, compared to its average volume of 1,410,549. The company’s 50-day moving average is $1.20 and its two-hundred day moving average is $1.17. SELLAS Life Sciences Group has a twelve month low of $0.77 and a twelve month high of $1.84. The company has a market cap of $82.70 million, a P/E ratio of -1.70 and a beta of 2.43.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.